Literature DB >> 32124324

EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data.

Julien Racle1,2, David Gfeller3,4.   

Abstract

Gene expression profiling is nowadays routinely performed on clinically relevant samples (e.g., from tumor specimens). Such measurements are often obtained from bulk samples containing a mixture of cell types. Knowledge of the proportions of these cell types is crucial as they are key determinants of the disease evolution and response to treatment. Moreover, heterogeneity in cell type proportions across samples is an important confounding factor in downstream analyses.Many tools have been developed to estimate the proportion of the different cell types from bulk gene expression data. Here, we provide guidelines and examples on how to use these tools, with a special focus on our recent computational method EPIC (Estimating the Proportions of Immune and Cancer cells). EPIC includes RNA-seq-based gene expression reference profiles from immune cells and other nonmalignant cell types found in tumors. EPIC can additionally manage user-defined gene expression reference profiles. Some unique features of EPIC include the ability to account for an uncharacterized cell type, the introduction of a renormalization step to account for different mRNA content in each cell type, and the use of single-cell RNA-seq data to derive biologically relevant reference gene expression profiles. EPIC is available as a web application ( http://epic.gfellerlab.org ) and as an R-package ( https://github.com/GfellerLab/EPIC ).

Entities:  

Keywords:  Cell fraction predictions; Computational biology; Gene expression analysis; Immunoinformatics; RNA-seq deconvolution; Tumor immune microenvironment

Mesh:

Substances:

Year:  2020        PMID: 32124324     DOI: 10.1007/978-1-0716-0327-7_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  65 in total

1.  Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma.

Authors:  Di-Guang Wen; Xiao-Ping Zhao; Yu You; Zuo-Jin Liu
Journal:  Cancer Immunol Immunother       Date:  2020-09-28       Impact factor: 6.968

2.  Identification of Lactate-Related Gene Signature for Prediction of Progression and Immunotherapeutic Response in Skin Cutaneous Melanoma.

Authors:  Yalin Xie; Jie Zhang; Mengna Li; Yu Zhang; Qian Li; Yue Zheng; Wei Lai
Journal:  Front Oncol       Date:  2022-02-21       Impact factor: 6.244

3.  Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Roni Shouval; Ana Alarcon Tomas; Joshua A Fein; Jessica R Flynn; Ettai Markovits; Shimrit Mayer; Aishat Olaide Afuye; Anna Alperovich; Theodora Anagnostou; Michal J Besser; Connie Lee Batlevi; Parastoo B Dahi; Sean M Devlin; Warren B Fingrut; Sergio A Giralt; Richard J Lin; Gal Markel; Gilles Salles; Craig S Sauter; Michael Scordo; Gunjan L Shah; Nishi Shah; Ruth Scherz-Shouval; Marcel van den Brink; Miguel-Angel Perales; Maria Lia Palomba
Journal:  J Clin Oncol       Date:  2021-12-03       Impact factor: 44.544

4.  Necroptosis-Related LncRNA Signatures for Prognostic Prediction in Uterine Corpora Endometrial Cancer.

Authors:  Juntao Wang; Junde Zhao; Zhiheng Lin; Weisen Fan; Xiaohui Sui
Journal:  Reprod Sci       Date:  2022-07-19       Impact factor: 2.924

5.  Risk coefficient model of necroptosis-related lncRNA in predicting the prognosis of patients with lung adenocarcinoma.

Authors:  GenYi Qu; NianXi Tan; HuiWei Chen; Zhimin Xie; QingZhu Li; YuLong Zhang
Journal:  Sci Rep       Date:  2022-06-29       Impact factor: 4.996

6.  Characteristics of Prognostic Programmed Cell Death-Related Long Noncoding RNAs Associated With Immune Infiltration and Therapeutic Responses to Colon Cancer.

Authors:  Yan Chen; Yue Zhang; Jiayi Lu; Zhongchen Liu; Shasha Zhao; Mengmei Zhang; Mingzhi Lu; Wen Xu; Fenyong Sun; Qi Wu; Qi Zhong; Zhongqi Cui
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

7.  Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer.

Authors:  Pratyaksha Wirapati; Nancy Zhao; Zahid Nawaz; Ignasius Joanito; Grace Yeo; Fiona Lee; Christine L P Eng; Dominique Camat Macalinao; Merve Kahraman; Harini Srinivasan; Vairavan Lakshmanan; Sara Verbandt; Petros Tsantoulis; Nicole Gunn; Prasanna Nori Venkatesh; Zhong Wee Poh; Rahul Nahar; Hsueh Ling Janice Oh; Jia Min Loo; Shumei Chia; Lih Feng Cheow; Elsie Cheruba; Michael Thomas Wong; Lindsay Kua; Clarinda Chua; Andy Nguyen; Justin Golovan; Anna Gan; Wan-Jun Lim; Yu Amanda Guo; Choon Kong Yap; Brenda Tay; Yourae Hong; Dawn Qingqing Chong; Aik-Yong Chok; Woong-Yang Park; Shuting Han; Mei Huan Chang; Isaac Seow-En; Cherylin Fu; Ronnie Mathew; Ee-Lin Toh; Lewis Z Hong; Anders Jacobsen Skanderup; Ramanuj DasGupta; Chin-Ann Johnny Ong; Kiat Hon Lim; Emile K W Tan; Si-Lin Koo; Wei Qiang Leow; Sabine Tejpar; Shyam Prabhakar; Iain Beehuat Tan
Journal:  Nat Genet       Date:  2022-06-30       Impact factor: 41.307

Review 8.  Unlocking immune-mediated disease mechanisms with transcriptomics.

Authors:  Emma de Jong; Anthony Bosco
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

9.  Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma.

Authors:  Jie Yao; Xiao Chen; Xiao Liu; Rui Li; Xijia Zhou; Yiqing Qu
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722

10.  Establishment of an Immune Cell Infiltration Score to Help Predict the Prognosis and Chemotherapy Responsiveness of Gastric Cancer Patients.

Authors:  Quan Jiang; Jie Sun; Hao Chen; Chen Ding; Zhaoqing Tang; Yuanyuan Ruan; Fenglin Liu; Yihong Sun
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.